Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 15;13(7):7960-7967.
eCollection 2021.

Clinical intervention effect of TACE combined with 3DCRT in patients with primary liver cancer

Lifeng Xie  1 , Zhuliang Qian  1 , Jianchang Xu  1
Affiliations

Clinical intervention effect of TACE combined with 3DCRT in patients with primary liver cancer

Lifeng Xie et al. Am J Transl Res. .

Abstract

Objective: To investigate the clinical intervention effect of transcatheter arterial chemoembolization (TACE) combined with three-dimensional conformal radiotherapy (3DCRT) in patients with primary liver cancer (PLC).

Methods: A total of 110 PLC patients admitted to our hospital were selected and divided into the study group (SG, n=60, treated with TACE combined with 3DCRT) and the control group (CG, n=50, treated with TACE alone) in accordance with the different clinical intervention measures. The clinical intervention effect and the changes of tumor factors and quality of life scores were compared between the two groups before and after intervention, and the three-year survival and the incidence of adverse reactions were evaluated.

Results: The objective response rate (ORR) and disease control rate (DCR) in the SG (78.33% and 95.00%) were higher than those in the CG (38.00% and 80.00%), whereas the carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) levels in the SG were lower than those in the CG (P < 0.05). After intervention, the quality of life score in the SG was higher than that in the CG (P < 0.05). The SG was superior to the CG in follow-up survival (P < 0.05).

Conclusion: TACE combined with 3DCRT has a high safety and leads to remarkable clinical intervention effects, marked improvement of the serological indices, better quality of life, as well as satisfactory long-term survival.

Keywords: 3DCRT; TACE; clinical intervention; effect; influence; primary liver cancer.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Analysis of changes of serological indices in the two groups during the intervention. The analysis of changes in AFP (A) and CEA (B) levels in the two groups were analyzed. The results revealed that the AFP and CEA levels in the two groups showed a downward trend during treatment, and the AFP and CEA levels in the study group were lower than those in the control group at 3, 6, 12 and 24 months after intervention (P < 0.05). #indicates a statistically significant difference in the same indices at the same time points between the two groups.
Figure 2
Figure 2
Analysis of changes of quality of life in the two groups before and after intervention. There was no statistically significant difference in the scores of KPS and QOL scale between the two groups before intervention (P > 0.05). After intervention, the scores of KPS and QOL scale in the study group were noticeably higher than those in the control group (P < 0.05). #indicates a statistically significant difference in the same indices between the two groups.
Figure 3
Figure 3
Evaluation of survival rates in the two groups. The survival rate in the study group was significantly higher than that in the control group at 12, 24 and 36 months after intervention (P < 0.05). #indicates a statistically significant difference in the survival rate at the same time points between the two groups.
See this image and copyright information in PMC

References

    1. Ma X, Tan YT, Yang Y, Gao J, Li HL, Zheng W, Lan Q, Rothman N, Shu XO, Xiang YB. Pre-diagnostic urinary 15-F2t-isoprostane level and liver cancer risk: results from the Shanghai women’s and men’s health studies. Int J Cancer. 2018;143:1896–1903. - PMC - PubMed
    1. Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P, Haybaeck J. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 2017;83:56–70. - PubMed
    1. Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, Dong P, Bai FZ, Yan XL, Liao XZ, Liu GX, Bai YN, Ren JS, Sun XJ, Zhu XY, Zhou JY, Gong JY, Zhu L, Mai L, Du LB, Zhou Q, Xing XJ, Song BB, Liu YQ, Lou PA, Sun XH, Wu SL, Cao R, Qi X, Lan L, Ren Y, Zhang K, He J, Qu C, Dai M. Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002-2011) J Cancer Res Ther. 2018;14:163–170. - PubMed
    1. Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell. 2018;33:1061–1077. e1066. - PMC - PubMed
    1. Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control. 2018;25:1073274817744621. - PMC - PubMed